로딩 중…
지수 로딩 중…
Agios Pharmaceuticals, Inc.
AGIO· NASDAQ· Health Care· Pharmaceuticals, Biotechnology & Life Sciences
$30.54+1.73%
2026-08-03
Financials
Valuation Metrics
Agios Pharmaceuticals, Inc.'s Market Cap is $1.82B. At end of 2025 it was $1.59B. Ranked #2121 of 3,112 in US market (top 68%), #823 of 1,445 on NASDAQ (top 57%), #148 of 269 in Pharmaceuticals, Biotechnology & Life Sciences (top 55%) by Market Cap.
Investment Metrics(as of 2026-08-03)
| Metric | Value | Rank |
|---|---|---|
| Size | ||
| Market Cap | $1.82B | US#2,121/3,112 Sec#148/269 |
| Revenue | $98M | US#2,783/3,112 Sec#126/269 |
| Net Income | $-411M | US—/3,112 Sec—/269 |
| Total Assets | $1.11B | US#2,403/3,112 Sec#92/269 |
| Net Assets | $1.03B | US#1,762/3,112 Sec#61/269 |
| Value | ||
| P/B | 1.77x | US#1,040/3,112 Sec#47/269 |
| P/S | 18.47x | US#2,799/3,112 Sec#143/269 |
| FCF Yield | -20.11% | US—/3,112 Sec—/269 |
| Profitability | ||
| ROE | -40.09% | US#2,695/3,112 Sec#153/269 |
| ROA | -37.11% | US#2,914/3,112 Sec#183/269 |
| Op. Margin | -466.78% | US#2,895/3,112 Sec#161/269 |
| Revenue Growth | 259.25% | US#55/3,112 Sec#18/269 |
| Earnings Growth | -161.27% | US#2,190/3,112 Sec#75/269 |
| Financial Health | ||
| Debt Ratio | 8.03% | US#82/3,112 Sec#37/269 |
| Total Debt | $31M | US#2,633/3,112 Sec#167/269 |
| FCF | $-365M | US#2,804/3,112 Sec#247/269 |
| Cash | $100M | US#2,214/3,112 Sec#177/269 |
| Current Ratio | 10.22x | US#246/3,112 Sec#78/269 |
| Performance | ||
| 1Y Return | -12.74% | US#2,482/3,112 Sec#216/269 |
| 1M Return | -18.73% | US#2,928/3,112 Sec#229/269 |
| From 52W High | -33.61% | US#2,307/3,112 Sec#175/269 |
| 1Y MDD | -50.89% | US#2,437/3,112 Sec#188/269 |
| Trading | ||
| Volume | 1,156,331 shares | US#1,354/3,112 Sec#136/269 |
| Trading Value | $35M | US#1,622/3,112 Sec#108/269 |
| Per Share | ||
| EPS | $-7.07 | US—/3,112 Sec—/269 |
| BPS | $20.45 | US#1,177/3,112 Sec#32/269 |